甲状腺微小乳头状癌高侵袭性的解读

doi:10.16139/j.1007-9610.2021.06.005

摘要/Abstract

中图分类号:

R736.1

王旭东. 甲状腺微小乳头状癌高侵袭性的解读[J]. 外科理论与实践, 2021, 26(06): 486-492.

WANG Xudong. Interpretation of more aggressive papillary thyroid microcarcinoma[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 486-492.

参考文献 61

[1]	Hedinger CE, Williams ED, Sobin LH. Histological ty-ping of thyroid tumours[M]//The WHO international histo-logical classification of tumours, 2nd edn. Berlin: Springer-Verlag, 1988.
[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3]	Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? an analysis of 18,445 cases[J]. Ann Surg, 2011, 254(4):653-660.
[4]	Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes[J]. World J Surg, 2010, 34(6):1222-1231.
[5]	Haugen BR, Alexander EK, Bible KC, et al. 2015 Ame-rican Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
[6]	中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016, 43(10):405-411.
[7]	Sugitani I, Ito Y, Takeuchi D, et al. Indications and stra-tegy for active surveillance of adult low-risk papillary thyroid microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery task force on management for papillary thyroid microcarcinoma[J]. Thyroid, 2021, 31(2):183-192.
[8]	Kasai N, Sakamoto A. New subgrouping of small thyroid carcinomas[J]. Cancer, 1987, 60(8):1767-1770.
[9]	Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality[J]. Cancer, 2003, 98(1):31-40.
[10]	Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients[J]. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
[11]	Roti E, Rossi R, Trasforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients[J]. J Clin Endocrinol Metab, 2006, 91(6):2171-2178.
[12]	Ito Y, Miyauchi A, Oda H, et al. Revisiting low-risk thyroid papillary microcarcinomas resected without observation: was immediate surgery necessary?[J]. World J Surg, 2016, 40(3):523-528.
[13]	Bansal M, Gandhi M, Ferris RL, et al. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma[J]. Am J Surg Pathol, 2013, 37(10):1586-1591.
[14]	So YK, Kim MW, Son YI. Multifocality and bilaterality of papillary thyroid microcarcinoma[J]. Clin Exp Otorhinolaryngol, 2015, 8(2):174-178.
[15]	Kaliszewski K, Diakowska D, Wojtczak B, et al. The occurrence of and predictive factors for multifocality and bilaterality in patients with papillary thyroid microcarcinoma[J]. Medicine (Baltimore), 2019, 98(19):e15609.
[16]	Harries V, Wang LY, McGill M, et al. Should multifoca-lity be an indication for completion thyroidectomy in pa-pillary thyroid carcinoma?[J]. Surgery, 2020, 167(1):10-17.
[17]	Tallini G, De Leo A, Repaci A, et al. Does the site of origin of the microcarcinoma with respect to the thyroid surface matter? a multicenter pathologic and clinical study for risk stratification[J]. Cancers (Basel), 2020, 12(1):246.
[18]	Al-Qurayshi Z, Nilubol N, Tufano RP, et al. Wolf in sheep′s clothing: papillary thyroid microcarcinoma in the US[J]. J Am Coll Surg, 2020, 230(4):484-491.
[19]	Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update[J]. Endocr Pract, 2016, 22(5):622-639.
[20]	Lloyd RV, Osamura RY, Klöppel G,Eds. WHO Classification of Tumours of Endocrine Organs[M]. 4th ed. WHO/IARC: Lyon, France, 2017,Volume10.
[21]	Ho AS, Luu M, Barrios L, et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma[J]. [published correction appears in JAMA Oncol,2020,6(5):789]. JAMA Oncol, 2020, 6(5):706-713.
[22]	Kuo EJ, Goffredo P, Sosa JA, et al. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis[J]. Thyroid, 2013, 23(10):1305-1311.
[23]	Holoubek SA, Yan H, Khokar AH, et al. Aggressive variants of papillary thyroid microcarcinoma are associ-ated with high-risk features, but not decreased survival[J]. Surgery, 2020, 167(1):19-27.
[24]	Jin M, Song DE, Ahn J, et al. Genetic profiles of aggressive variants of papillary thyroid carcinomas[J]. Cancers (Basel), 2021, 13(4):892.
[25]	Kim BK, Choi YS, Kwon HJ, et al. Relationship between patterns of calcification in thyroid nodules and histopathologic findings[J]. Endocr J, 2013, 60(2):155-160.
[26]	Chung SR, Baek JH, Choi YJ, et al. Diagnostic algorithm for metastatic lymph nodes of differentiated thyroid carcinoma[J]. Cancers(Basel), 2021, 13(6):1338.
[27]	Oh EM, Chung YS, Song WJ, et al. The pattern and significance of the calcifications of papillary thyroid microcarcinoma presented in preoperative neck ultrasonography[J]. Ann Surg Treat Res, 2014, 86(3):115-121.
[28]	张帅, 谷文青, 胡传祥, 等. 弥漫钙化型甲状腺癌的临床生物学特性研究[J]. 中华普通外科杂志, 2020, 35(11):862-865.
[29]	Peng Q, Zhang Q, Chen S, et al. Petal-like calcifications in thyroid nodules on ultrasonography: a rare morphologic characteristic of calcification associated with aggressive biological behavior[J]. Front Endocrinol (Lausanne), 2020, 11:271.
[30]	Na DG, Kim DS, Kim SJ, et al. Thyroid nodules with isolated macrocalcification: malignancy risk and diagnostic efficacy of fine-needle aspiration and core needle biopsy[J]. Ultrasonography, 2016, 35(3):212-219.
[31]	Gwon HY, Na DG, Noh BJ, et al. Thyroid nodules with isolated macrocalcifications: malignancy risk of isolated macrocalcifications and postoperative risk stratification of malignant tumors manifesting as isolated macrocalcifications[J]. Korean J Radiol, 2020, 21(5):605-613.
[32]	Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(1):17-29.
[33]	Kitahara CM, Sosa JA. The changing incidence of thyroid cancer[J]. Nat Rev Endocrinol, 2016, 12(11):646-653.
[34]	Choi JS, Kim EK, Moon HJ, et al. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma[J]. Endocrine, 2015, 48(1):264-271.
[35]	Trésallet C, Seman M, Tissier F, et al. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices[J]. Surgery, 2014, 156(5):1145-1152.
[36]	Pazaitou-Panayiotou K, Polyzos SA, Mantzoros CS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms[J]. Obes Rev, 2013, 14(12):1006-1022.
[37]	Wang X, Cheng W, Li J, et al. Endocrine tumours: fami-lial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis[J]. Eur J Endocrinol, 2015, 172(6):R253-R262.
[38]	Capezzone M, Secchi C, Fralassi N, et al. Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma?[J]. J Endocrinol Invest, 2019, 42(10):1205-1213.
[39]	Lee CR, Park S, Kang SW, et al. Is familial papillary thyroid microcarcinoma more aggressive than sporadic form?[J]. Ann Surg Treat Res, 2017, 92(3):129-135.
[40]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[41]	Dai YJ, Qiu YB, Jiang R, et al. Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas[J]. Sci Rep, 2017, 7(1):12279.
[42]	Derwahl M, Nicula D. Estrogen and its role in thyroid cancer[J]. Endocr Relat Cancer, 2014, 21(5):T273-T283.
[43]	Shindo H, Amino N, Ito Y, et al. Papillary thyroid microcarcinoma might progress during pregnancy[J]. Thyroid, 2014, 24(5):840-844.
[44]	Rakhlin L, Fish S, Tuttle RM. Response to therapy status is an excellent predictor of pregnancy-associated structural disease progression in patients previously treated for differentiated thyroid cancer[J]. Thyroid, 2017, 27(3):396-401.
[45]	Liu Y, Li C, Zhao W, et al. Hashimoto's thyroiditis is an important risk factor of papillary thyroid microcarcinoma in younger adults[J]. Horm Metab Res, 2017, 49(10):732-738.
[46]	Qu N, Zhang L, Lin DZ, et al. The impact of coexistent Hashimoto′s thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma[J]. Tumour Biol, 2016, 37(6):7685-7692.
[47]	Tam AA, Ozdemir D, Aydın C, et al. Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer[J]. Endocrine, 2018, 59(3):565-572.
[48]	Li F, Chen G, Sheng C, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis[J]. Endocr Relat Cancer, 2015, 22(2):159-168.
[49]	Samà MT, Grosso E, Mele C, et al. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma[J]. Endocrine, 2021, 71(1):149-157.
[50]	Kim KJ, Kim SG, Tan J, et al. BRAFV600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma[J]. Eur J Cancer, 2020, 124:161-169.
[51]	de Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013-1019.
[52]	Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
[53]	Huang M, Yan C, Xiao J, et al. Relevance and clinicopathologic relationship of BRAFV600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in northwest China[J]. Diagn Pathol, 2019, 14(1):74.
[54]	Xing M. Genetic-guided risk assessment and management of thyroid cancer[J]. Endocrinol Metab Clin North Am, 2019, 48(1):109-124.
[55]	罗定远, 廖健伟. 甲状腺癌基因检测与临床应用广东专家共识(2020版)[J]. 中华普通外科学文献(电子版), 2020, 14(3):161-168.
[56]	Shen R, Liyanarachchi S, Li W, et al. MicroRNA signature in thyroid fine needle aspiration cytology applied to “atypia of undetermined significance” cases[J]. Thyroid, 2012, 22(1):9-16.
[57]	Zhang Y, Pan J, Xu D, et al. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma[J]. Oncol Rep, 2018, 40(6):3611-3624.
[58]	Pan W, Zhou L, Ge M, et al. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations[J]. Hum Mol Genet, 2016, 25(9):1875-1884.
[59]	张冬雪, 刘欣, 陈振文, 等. 长链非编码RNA GAS8-AS1在甲状腺微小乳头状癌中的表达特点及临床意义分析[J]. 中华内分泌代谢杂志, 2017, 33(8):687-692.
[60]	Lan X, Xu J, Chen C, et al. The landscape of circular RNA expression profiles in papillary thyroid carcinoma based on RNA sequencing[J]. Cell Physiol Biochem, 2018, 47(3):1122-1132.
[61]	Yang W, Bai C, Zhang L, et al. Correlation between serum circRNA and thyroid micropapillary carcinoma with cervical lymph node metastasis[J]. Medicine(Baltimore), 2020, 99(47):e23255.

甲状腺微小乳头状癌高侵袭性的解读

Interpretation of more aggressive papillary thyroid microcarcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 61

相关文章 7

编辑推荐

Metrics

本文评价

[1]	樊金芳, 沈依, 詹维伟, 陶玲玲, 李伟伟, 况李君, 周伟. 峡部甲状腺微小乳头状癌临床病理分析[J]. 外科理论与实践, 2021, 26(06): 528-531.
[2]	王院霞, 姚锂凤, 郑巧平, 陈旭. 9株分离自住院患者的CA-MRSA基因型菌株的分子特征及耐药性研究[J]. 诊断学理论与实践, 2021, 20(01): 66-70.
[3]	郭颖, 郑蕾, 张世瑜, 杨卫平, 严佶祺, 匡洁, 陈曦. 甲状腺微小乳头状癌根治术后的专科随访[J]. 外科理论与实践, 2019, 24(03): 254-258.
[4]	张璐, 彭艳, 周伟, 詹维伟, 徐瑛, 朱樱, 胡赟赟,. 超声引导经皮激光消融治疗甲状腺微小乳头状癌的疗效[J]. 外科理论与实践, 2017, 22(05): 433-437.
[5]	康慧莉, 董屹婕, 詹维伟. 甲状腺微小乳头状癌淋巴结转移的相关因素研究[J]. 诊断学理论与实践, 2016, 15(05): 482-486.
[6]	周伟, 詹维伟, 叶廷军, 曹毅, 朱樱, 胡赟赟, 姚洁洁,. 超声引导下经皮激光消融治疗甲状腺微小乳头状癌(附3例报告)[J]. 外科理论与实践, 2014, 19(02): 131-135.
[7]	高明, 赵敬柱,. 甲状腺微小乳头状癌诊治探讨[J]. 内科理论与实践, 2013, 8(06): 388-391.